Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Lexaria Bioscience (LEXX) announced that its Contract Research Organization has completed the important study milestone known ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Lupin Limited has received the green light from the Subject Expert Committee (SEC) under the Endocrinology & Metabolism ...

The updated recommendations also address the link between high blood pressure and cognitive decline and dementia.